pharmaphorum.com
Beyond omnichannel: Why pharma commercialisation must shift to omnideployment
We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
#PatientSupport is an active hashtag on Bluesky. In the last 30 days, 13 people shared 23 posts with it — around 1 a day. Activity is up 17% versus the previous week, peaking on Sep 14 with 3 posts.
Tags most often used together with #PatientSupport.
pharmaphorum.com
Beyond omnichannel: Why pharma commercialisation must shift to omnideployment
We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
www.easterneye.biz
Enhertu: What to Know About NHS Breast Cancer Treatment
Enhertu is being used as a targeted treatment for eligible breast cancer patients. Here’s what patients should know about the therapy.
citizenportal.ai
LivingLink wins $1M grand prize for FHIR‑based donor navigation platform
LivingLink, an open‑source FHIR‑enabled donor navigation platform, won the $1 million grand prize for its five‑module approach to donor readiness, financial counseling, mentoring, evaluation tracking and post‑donation follow‑up.
citizenportal.ai
LivingLink wins $1M grand prize for FHIR‑based donor navigation platform
LivingLink, an open‑source FHIR‑enabled donor navigation platform, won the $1 million grand prize for its five‑module approach to donor readiness, financial counseling, mentoring, evaluation tracking and post‑donation follow‑up.
www.easterneye.biz
Enhertu: What to Know About NHS Breast Cancer Treatment
Enhertu is being used as a targeted treatment for eligible breast cancer patients. Here’s what patients should know about the therapy.
pharmaphorum.com
Beyond omnichannel: Why pharma commercialisation must shift to omnideployment
We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
citizenportal.ai
PCAhead pathways: CMS details enhanced primary care payments, four participation tracks and quality-based adjustments
PCAhead will offer four participation pathways (basic, advanced fee-for-service, advanced hybrid, advanced capitated) and an EPCP payment averaging $17–$21 per beneficiary per month, adjusted by Medical Risk Adjustment, Population Adjustment, and a 5–15% Quality-Based Adjustment tied to performance.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.